Sirtuin 1 activator SRT1720 protects against lung injury via reduction of type II alveolar epithelial cells apoptosis in emphysema

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 12, Issue 4, 2015, Pages 444-452

  Gu, Chao ^a,b   Li, Yaqing ^a   Xu, Wu Lin ^a   Yan, Jian Ping ^a   Xia, Ying Jie ^a   Ma, Ying Yu ^a   Chen, Chun ^a   Wang, Hui Ju ^a   Tao, Hou Quan ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

alveolar epithelial cells; apoptosis; chronic obstructive pulmonary disease; sirtuin 1

Indexed keywords

CIGARETTE SMOKE; LIPOPOLYSACCHARIDE; MESSENGER RNA; N [2 [3 (1 PIPERAZINYLMETHYL)IMIDAZO[2,1 B]THIAZOL 6 YL]PHENYL] 2 QUINOXALINECARBOXAMIDE; PROTEIN P53; SIRTUIN 1; TRANSCRIPTION FACTOR FKHRL1; BIOLOGICAL MARKER; ENZYME ACTIVATOR; FUSED HETEROCYCLIC RINGS;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DOWN REGULATION; EMPHYSEMA; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM CELL; LUNG COMPLIANCE; LUNG FUNCTION; LUNG INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; UPREGULATION; ANIMAL; COMPLICATION; DRUG EFFECTS; EVALUATION STUDY; LUNG ALVEOLUS CELL; METABOLISM; PHYSIOLOGY; PULMONARY EMPHYSEMA; RANDOMIZATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; TUNEL ASSAY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BIOMARKERS; BLOTTING, WESTERN; ENZYME ACTIVATORS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LUNG INJURY; MALE; PNEUMOCYTES; PULMONARY EMPHYSEMA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84939426103     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.974740     Document Type: Article

References (46)

1. Mizutani N, Fuchikami J, Takahashi M, Nabe T, Yoshino S, Kohno S. Pulmonary emphysema induced by cigarette smoke solution and lipopolysaccharide in guinea pigs. Biol Pharm Bull 2009; 32 (9): 1559-1564
2. Burgel PR. Pathogenesis of chronic obstructive pulmonary disease. Presse Med 2009; 38 (3): 406-412
3. Siganaki M, Koutsopoulos AV, Neofytou E, Vlachaki E, Psarrou M, Soulitzis N, Pentilas N, Schiza S, Siafakas NM, Tzortzaki EG. Deregulation of apoptosis mediators p53 and bcl2 in lung tissue of COPD patients. Respir Res 2010; 11: 46
4. Zhao CZ, Fang XC, Wang D, Tang FD, Wang XD. Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease. Respir Med 2010; 104 (10): 1391-1395
5. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61: 105-119
6. Hoffman AM, Ingenito EP. Alveolar epithelial stem and progenitor cells: emerging evidence for their role in lung regeneration. Curr Med Chem 2012; 19 (35): 6003-6008
7. Milne JC, Denu JM. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 2008; 12 (1): 11-17
8. Bordo D. Structure and evolution of human sirtuins. Curr Drug Targets 2013; 14 (6): 662-665
9. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-Associated diseases. Nat Rev Drug Discov 2008; 7 (10): 841-853
10. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460 (7255): 587-591
11. Satoh A, Stein L, Imai S. The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handbk Exp Pharmacol 2011; 206: 125-162
12. Ichikawa T, Hayashi R, Suzuki K, Imanishi S, Kambara K, Okazawa S, Inomata M, Yamada T, Yamazaki Y, Koshimizu Y, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Sasahara M, Tobe K. Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma. Respirology 2013; 18 (2): 332-339
13. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450 (7170): 712-716
14. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Mataki C, Elliott PJ, Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008; 8 (5): 347-358
15. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100 (10): 1512-1521
16. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM. The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int 2013; 83 (3): 404-413
17. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177 (8): 861-870
18. Rahman I, Kinnula VL, Gorbunova V, Yao H. SIRT1 as a therapeutic target in inflammaging of the pulmonary disease. Prev Med 2012; 54 Suppl: S20-S28
19. Yao H, Chung S, Hwang JW, Rajendrasozhan S, Sundar IK, Dean DA, McBurney MW, Guarente L, Gu W, Rönty M, Kinnula VL, Rahman I. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 2012; 122 (6): 2032-2045
20. Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM, Abdelmohsen K, Shin YK, Canto C, Scheibye-Knudsen M, Krawczyk M, Irusta PM, Martín-Montalvo A, Hubbard BP, Zhang Y, Lehrmann E, White AA, Price NL, Swindell WR, Pearson KJ, Becker KG, Bohr VA, Gorospe M, Egan JM, Talan MI, Auwerx J, Westphal CH, Ellis JL, Ungvari Z, Vlasuk GP, Elliott PJ, Sinclair DA, de Cabo R. SRT1720 improves survival and healthspan of obese mice. Sci Rep 2011; 1: 70
21. Zheng H, Liu Y, Huang T, Fang Z, Li G, He S. Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke. Toxicol Lett 2009; 189 (3): 225-234
22. Jiang H, Zhu Y, Xu H, Sun Y, Li Q. Activation of hypoxia-inducible factor-1alpha via nuclear factor-kappa B in rats with chronic obstructive pulmonary disease. Acta Biochim Biophys Sin (Shanghai) 2010; 42 (7): 483-488
23. Agarwal AR, Yin F, Cadenas E. Short-Term cigarette smoke exposure leads to metabolic alterations in lung alveolar cells. Am J Respir Cell Mol Biol 2014; 51 (2): 284-293
24. Li Y, Xu W, Yan J, Xia Y, Gu C, Ma Y, Tao H. Differentiation of human amniotic fluid-derived mesenchymal stem cells into type II alveolar epithelial cells in vitro. Int J Mol Med 2014; 33 (6): 1507-1513
25. Farkas L, Farkas D, Warburton D, Gauldie J, Shi W, Stampfli MR, Voelkel NF, Kolb M. Cigarette smoke exposure aggravates air space enlargement and alveolar cell apoptosis in Smad3 knockout mice. Am J Physiol Lung Cell Mol Physiol 2011; 301 (4): L391-401
26. Caito S, Rajendrasozhan S, Cook S, Chung S, Yao H, Friedman AE, Brookes PS, Rahman I. SIRT1 is a redox-sensitive deacetylase that is post-Translationally modified by oxidants and carbonyl stress. FASEB J 2010; 24 (9): 3145-3159
27. Macnee W. Pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med 2007; 28 (3): 479-513
28. Martin TR. Recognition of bacterial endotoxin in the lungs. Am J Respir Cell Mol Biol 2000; 23 (2): 128-132
29. Fujino N, Kubo H, Suzuki T, Ota C, Hegab AE, He M, Suzuki S, Suzuki T, Yamada M, Kondo T, Kato H, Yamaya M. Isolation of alveolar epithelial type II progenitor cells from adult human lungs. Lab Invest 2011; 91 (3): 363-378
30. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 2003; 28 (5): 555-562
31. Mimae T, Hagiyama M, Inoue T, Yoneshige A, Kato T, Okada M, Murakami Y, Ito A. Increased ectodomain shedding of lung epithelial cell adhesion molecule 1 as a cause of increased alveolar cell apoptosis in emphysema. Thorax 2014; 69 (3): 223-231
32. Hara H, Araya J, Takasaka N, Fujii S, Kojima J, Yumino Y, Shimizu K, Ishikawa T, Numata T, Kawaishi M, Saito K, Hirano J, Odaka M, Morikawa T, Hano H, Nakayama K, Kuwano K. Involvement of creatine kinase B in cigarette smoke-induced bronchial epithelial cell senescence. Am J Respir Cell Mol Biol 2012; 46 (3): 306-312
33. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, Elliot M, Hogg J, Kharitonov S, Goto H, Bemis JE, Elliott P, Barnes PJ, Ito K A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009; 23 (9): 2810-2819
34. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006; 61 (3): 259-266
35. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G, Luisetti M, Annovazzi L, Iadarola P, De Rosa E, Fabbri LM, Mapp CE. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006; 61 (12): 1037-1042
36. Ilumets H, Rytilä P, Demedts I, Brusselle GG, Sovijärvi A, Myllärniemi M, Sorsa T, Kinnula VL. Matrix metalloproteinases-8,-9 and-12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis 2007; 2 (3): 369-379
37. Macnee W, Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160 (5 Pt 2): S58-S65
38. Yao H, Rahman I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol 2011; 254 (2): 72-85
39. Yao H, Hwang JW, Sundar IK, Friedman AE, McBurney MW, Guarente L, Gu W, Kinnula VL, Rahman I. SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. Am J Physiol Lung Cell Mol Physiol 2013; 305 (9): L615-L624
40. Yao H, Sundar IK, Ahmad T, Lerner C, Gerloff J, Friedman AE, Phipps RP, Sime PJ, McBurney MW, Guarente L, Rahman I. SIRT1 protects against cigarette smoke-induced lung oxidative stress via a FOXO3-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2014; 306 (9): L816-L828
41. Zhang T, Rong N, Chen J, Zou C, Jing H, Zhu X, Zhang W. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS One 2013; 8 (11): e79162
42. Chen X, Hokka D, Maniwa Y, Ohbayashi C, Itoh T, Hayashi Y. Sirt1 is a tumor promoter in lung adenocarcinoma. Oncol Lett 2014; 8 (1): 387-393
43. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-The p53 network. J Cell Sci 2003; 116 (Pt 20): 4077-4085
44. Weaver CV, Liu SP. Differentially expressed pro-And anti-Apoptogenic genes in response to benzene exposure: Immunohistochemical localization of p53, Bag, Bad, Bax, Bcl-2, and Bcl-w in lung epithelia. Exp Toxicol Pathol 2008; 59 (5): 265-272
45. Arunachalam G, Samuel SM, Marei I, Ding H, Triggle CR. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 2014; 171 (2): 523-535
46. Ganesan S, Unger BL, Comstock AT, Angel KA, Mancuso P, Martinez FJ, Sajjan US. Aberrantly activated EGFR contributes to enhanced IL-8 expression in COPD airways epithelial cells via regulation of nuclear FoxO3A. Thorax 2013; 68 (2): 131-141